TherapeuticsMD (TXMD) Misses Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts TXMD Hot Sheet
Join SI Premium – FREE
TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $5.63 million.
For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Fortive (FTV) Tops Q1 EPS by 4c ; Offers Guidance
- Norfolk Southern (NSC) Misses Q1 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
